A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.
Also called NCT04945460
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 165 participants
- Registry
-
NCT04945460 -
2023-509141-12-00 -
U1111-1309-6433 -
2021-003020-32
-
- Main results
- Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, France, Germany, Israel, Italy, Mexico, Poland, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04945460. Randomized; triple masking; primary purpose treatment. Start 2021-12-29 (actual); primary completion 2025-09-05 (actual). Results posted on 2026-09-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
- Acronym
- CADENCE
- Condition
- Hypertension, Pulmonary
- Intervention (Drug)
- Sotatercept 0.3 mg/kg
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Record details
- Record id
cardio:ct-nct04945460- Content hash
0368e6690cfc36a6c9de638e96010d8e3fa8254b07491aa0e080775785f03ad9